Abstract
Aim. To evaluate the efficiency and safety of intravitreal administration of brolucizumab in real clinical practice in the treatment of patients with neovascular form of age-related macular degeneration. Methods. The study included 89 patients with neovascular age-related macular degeneration, mean age 69.5±7.8 years, including 36 % men and 64 % women: group 1 – 17 patients who had not previously received anti VEGF therapy; group 2 – 72 patients with disease activity on the background of previous anti-VEGF therapy. Best corrected visual acuity was determined and the parameters of optical coherence tomography, biomicroscopic and ophthalmoscopic studies were evaluated. Results. Mean follow-up period was 51±3.4 weeks. The incidence of intraocular inflammation during brolucizumab therapy among patients who had not previously received anti-VEGF therapy was 0 %, against the background of previous anti-VEGF therapy – 1.4 %. Conclusions. Lower percentage of intraocular inflammation cases may be associated with careful selection of patients using exclusion criteria, assessment of the condition of the anterior and posterior segment of the eye. Key words: age-related macular degeneration; anti VEGF therapy; brolucizumab; intraocular inflammation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
